삼진제약 Stock: price and insider trades · South Korea

Every trade that managers of 삼진제약 disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 2 November 2026, brought 20 filings signed by 12 insiders.

Purchases and sales both appear in the filings: 11 purchases (8 insiders, €21k) and 4 sales (3 insiders). The totals do not cover 14 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 박창익 filed the largest purchase, €21k, on 15 April 2026, which represents 0.015% of the company's market value. Among those who bought: 4 board members, 2 senior executives and 2 chief executives.

The latest purchase dates back some time: it was published 67 days ago, on 2 September 2026. Typically, a trade is published a median of 8 days after it takes place. That lag is the time during which only the insider knows about the trade.

For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 20 filings here. Since 2021, the database holds 48 purchases and 7 sales by insiders of the company.

For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and UCB. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.